pyrotinib;CNS;breast cancer; HER-2 positivity
Showing 1 - 25 of >10,000
Breast Cancer Female Trial (Pyrotinib and Trastuzumab)
Not yet recruiting
- Breast Cancer Female
- Pyrotinib and Trastuzumab
- (no location specified)
Sep 11, 2023
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2
Recruiting
- HER2-positive Breast Cancer
- Early-stage Breast Cancer
- pyrotinib combined with Capecitabine
- treatment of physician's choice
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Sep 6, 2023
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,
Not yet recruiting
- Breast Cancer Invasive
- +3 more
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 17, 2023
Breast Cancer Trial in Xi'an (Disitamab Vedotin plus pyrotinib or naratinib)
Not yet recruiting
- Breast Cancer
- Disitamab Vedotin plus pyrotinib or naratinib
-
Xi'an, Shaanxi, ChinaXi'an International Medical Center Hospital
Aug 27, 2023
Breast Cancer Trial in Nanjing (Disitamb Vedotin ,pyrotinib)
Not yet recruiting
- Breast Cancer
- Disitamb Vedotin ,pyrotinib
-
Nanjing, Jiangsu, ChinaJiangsu Provincial People's Hospital
Aug 18, 2023
Breast Cancer Trial in Nanjing (Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate)
Recruiting
- Breast Cancer
- Inetetamab
- +2 more
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Apr 10, 2023
HER2 Positive Metastatic Breast Cancer Trial in Beijing (pyrotinib, , Capecitabine)
Active, not recruiting
- HER2 Positive Metastatic Breast Cancer
- pyrotinib
- +2 more
-
Beijing, China307 Hospital Affiliated to Academy Military Medical Science
Oct 24, 2022
Breast Cancer Trial in Yantai (pyrotinib combined with trastuzumab, dalpiciclib and letrozole)
Recruiting
- Breast Cancer
- pyrotinib combined with trastuzumab, dalpiciclib and letrozole
-
Yantai, Shandong, ChinaYantai Yuhuangding Hospital
Mar 23, 2023
Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic
Completed
- Breast Cancer
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 20, 2023
Breast Cancer, Neoadjuvant Trial in Wuhan (pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel)
Recruiting
- Breast Cancer
- Neoadjuvant
- pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel
-
Wuhan, Hubei, China
- +1 more
Aug 18, 2023
Locally Advanced Breast Cancer Trial in Shanghai (pyrotinib)
Recruiting
- Locally Advanced Breast Cancer
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 11, 2022
Breast Cancer With Brain Metastases Trial in Wuhan (pyrotinib+capecitabine+bevacizumab)
Recruiting
- Breast Cancer With Brain Metastases
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 22, 2023
HER2-positive Recurrent/Metastatic Breast Cancer Trial (Inetetamab, pyrotinib, chemo)
Not yet recruiting
- HER2-positive Recurrent/Metastatic Breast Cancer
- Inetetamab, pyrotinib, chemotherapy
- (no location specified)
Nov 16, 2022
Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
Not yet recruiting
- HER2-positive Breast Cancer
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Sep 28, 2022
Advanced/ Metastatic Her-2 Positive Breast Cancer Trial in Shanghai (GQ1001+pyrotinib, pyrotinib+capecitabine)
Active, not recruiting
- Advanced/ Metastatic Her-2 Positive Breast Cancer
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Nov 15, 2022
Breast Cancer, Brain Metastases, HER2-positive Breast Cancer Trial in Shanghai (Pyrotinib Plus Capecitabine combined with brain
Active, not recruiting
- Breast Cancer
- +2 more
- Pyrotinib Plus Capecitabine combined with brain radiotherapy
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Jan 14, 2023
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line
Recruiting
- Breast Neoplasms
- Inetetamab
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial People's Hospital
Mar 16, 2023
A Nationwide Multicenter, Ambispective Real-world Study of
Recruiting
- Breast Cancer
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Sep 15, 2022